Chronic intracerebroventricular TLQP-21 delivery does not modulate the GH/IGF-1-axis and muscle strength in mice

A. Bartolomucci, A. E. Rigamonti, I. Bulgarelli, A. Torsello, V. Locatelli, F. Pavone, A. Levi, R. Possenti, E. E. Muller, A. Moles

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Biallelic ablation of VGF determines a dwarf phenotype. VGF precursor protein encodes for different biologically active peptides none of which has been related to growth or muscular abnormalities. Here we present the first attempt to fill this gap. We tested the hypothesis that a recently identified VGF-derived peptide, TLQP-21, shown to centrally modulate metabolic functions, could also modulate growth hormone (GH)-axis and muscle strength. Design: Adult male mice were chronically icv injected with TLQP-21 (15 μg/day for 14 days). Physiological, molecular and behavioral parameters related to the GH/IGF-1-axis were investigated. Results: Except for a reduction in the soleus weight, TLQP-21 did not affect GH/IGF-1-axis mediators, muscle strength and muscle weight. Conclusions: Results collected exclude a role for TLQP-21 in modulating the GH/IGF1-axis and muscle functions. VGF-derived peptides involved in the dwarf phenotype of VGF-/- mice have to be identified yet.

Original languageEnglish
Pages (from-to)342-345
Number of pages4
JournalGrowth Hormone and IGF Research
Volume17
Issue number4
DOIs
Publication statusPublished - Aug 2007

Keywords

  • GH
  • GHRH
  • Grip strength test
  • IGF-1
  • Soleus
  • Somatostatin
  • VGF

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Chronic intracerebroventricular TLQP-21 delivery does not modulate the GH/IGF-1-axis and muscle strength in mice'. Together they form a unique fingerprint.

Cite this